We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,541

Bonus Episode: Interview with Professor Mary Bilder
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 13 2018

In this bonus episode, we had the pleasure of speaking with Professor Mary Bilder, the author of Madison’s Hand: Revising the Constitutional


Court Affirms Drug Conviction Notwithstanding Post-Trial E-mail from Juror Raising “Several Concerns”
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 13 2018

In United States v. Baker, the Court (Livingston, Chin, C.J.J., Koeltl, D.J.) affirmed the conviction of Raymond Baker, who after a jury trial in the


Judge Furman Stays Case Involving Possible Direct Competitors Pending IPR
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 13 2018

On August 8, 2018, Judge Jesse M. Furman (S.D.N.Y.) granted Defendant Synaptive Medical, Inc.’s (“Synaptive”) motion to stay proceedings pending inter


Judge Engelmayer Makes a “Curtain Call”
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 10 2018

That is, Judge Engelmayer makes a call on the meaning of certain shower curtain claims. On August 9, 2018, United States District Judge Paul


FDA Approves Pfizer’s Biosimilar of Neupogen as Amgen and Pfizer Litigate Patent Infringement
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 9 2018

On July 20, 2018, FDA approved Pfizer’s biosimilar of Amgen’s Neupogen (filgrastim). Pfizer’s product, Nivestym, is the second biosimilar of


Delaware Court Denies $60 Million Administrative Expense Claim in the EFH Case
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 9 2018

The Bankruptcy Court in Delaware recently denied a request for an administrative expense claim to an entity that tried but failed to buy a debtor’s


The More (Members) the Merrier? Or, So Long, Sole Members
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 9 2018

The New York Assembly and Senate recently passed legislation - A.B. 10336-A (Paulin) S.B. 8699 (Gallivan) (the “Bill”) - that would raise the


Week 10, Part 2: Don’t Forget Who Got You This Far
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 9 2018

Morris tries to save the country from aristocracy through aristocracy. Pinckney takes things too far on behalf of the 1. Conflicting principles and


Amgen Brings Third BPCIA Lawsuit Against Apotex After Losing Two Others
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 8 2018

Amgen has sued Apotex in connection with Apotex’s efforts to market biosimilar versions of Amgen’s cancer drugs Neupogen (filgrastim) and Neulasta


What New York Businesses Need to Know About California’s New Data Privacy Law
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 7 2018

As the home of Facebook and other tech giants, California recently found itself in the center of a data privacy firestorm. In response to this and